Ziphius Vaccines – a company developing vaccines and therapeutics based on self-amplifying RNA (saRNA), and UZ Ghent – have announced that they have entered a public-private collaboration.
The link-up involves the scale up and manufacturing of prophylactic self-amplifying RNA vaccines based on GMP (good manufacturing practice) standards.
The collaboration is a first in Europe where a university hospital produces GMP grade prophylactic saRNA vaccines for an industry partner. The partnership fits the Belgian government’s R&D Biopharma initiative where collaboration and coordination are encouraged to accelerate Belgium’s involvement in selected innovative platforms such as mRNA.
